To examine the role of exosomes in the management of dry eye disease (DED) and propose a novel framework for their application, specifically detailing the 'Triple Threat Approach'.
Key Findings:
Exosomes can mitigate inflammatory cascades and immune dysregulation in DED, as evidenced by recent studies.
They serve as effective drug delivery vehicles to target ocular tissues, improving therapeutic outcomes.
Exosome-associated molecular signatures enable non-invasive diagnosis and prognosis of DED, facilitating personalized treatment approaches.
Interpretation:
The integration of exosomes in DED management offers a multifaceted approach that enhances treatment efficacy and personalization, particularly through the 'Triple Threat Approach'.
Limitations:
Current challenges in clinical translation of exosome-based strategies, which may hinder their widespread adoption.
Limited understanding of exosome biogenesis and function in ocular tissues, impacting the development of effective therapies.
Conclusion:
The proposed 'Triple Threat Approach' emphasizes the synergistic use of exosomes in therapy, drug delivery, and diagnostics, paving the way for improved patient outcomes in DED and addressing current management gaps.
Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.
